Cullinan Associates’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-12,340
Closed -$1.23M 187
2019
Q3
$1.23M Hold
12,340
0.09% 120
2019
Q2
$1.14M Sell
12,340
-1,920
-13% -$182K 0.08% 123
2019
Q1
$1.34M Sell
14,260
-2,800
-16% -$245K 0.1% 124
2018
Q4
$1.09M Sell
17,060
-53,555
-76% -$3.95M 0.09% 122
2018
Q3
$6.32M Buy
70,615
+6,700
+10% +$592K 0.46% 65
2018
Q2
$5.08M Buy
63,915
+8,090
+14% +$672K 0.39% 73
2018
Q1
$4.98M Sell
55,825
-7,550
-12% -$725K 0.38% 77
2017
Q4
$6.61M Buy
63,375
+1,107
+2% +$125K 0.49% 51
2017
Q3
$9.08M Sell
62,268
-2,050
-3% -$279K 0.7% 41
2017
Q2
$8.35M Buy
64,318
+2,000
+3% +$245K 0.65% 44
2017
Q1
$7.75M Buy
62,318
+900
+1% +$108K 0.63% 45
2016
Q4
$7.11M Sell
61,418
-647
-1% -$72.1K 0.61% 46
2016
Q3
$6.49M Buy
62,065
+58
+0.1% +$6.28K 0.55% 46
2016
Q2
$6.12M Buy
62,007
+11,800
+24% +$1.22M 0.5% 54
2016
Q1
$5.03M Buy
50,207
+800
+2% +$82.4K 0.43% 67
2015
Q4
$5.92M Buy
49,407
+3,000
+6% +$347K 0.52% 49
2015
Q3
$5.02M Sell
46,407
-170
-0.4% -$21.1K 0.46% 54
2015
Q2
$5.39M Hold
46,577
0.44% 56
2015
Q1
$5.37M Buy
+46,577
New +$5.57M 0.42% 54

Other funds holding CELG

Cullinan Associates's CELG Position: Q4 2019 in Review

Cullinan Associates sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 12,340 shares — an estimated $1.23M sold.

Cullinan Associates first reported a position in CELG in Q1 2015 and held it in 19 quarters. The position peaked at $9.08M in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Cullinan Associates reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Cullinan Associates sold 12,340 Celgene Corp shares in Q4 2019, an estimated $1.23M.
  • Cullinan Associates first reported a position in Celgene Corp in Q1 2015 and held it in 19 quarters.
  • Cullinan Associates's Celgene Corp position peaked at $9.08M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Cullinan Associates's 13F filing for Q4 2019, filed 15 Jan 2020.